Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival

The incidence of cardiotoxicity among women treated with trastuzumab for HER2-positive MBC appeared higher than that reported in RCTs, particularly in elder patients. In spite of this, median survival, was, if anything, better.